Опыт клинического применения моксифлоксацина при инфекциях различной локализации

1. Pan X-S, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumonia. Antimicrob Agents Chemother 1996; 40: 2321–6.
2. Chen DK, McGeer А, DeAzavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–9.
3. Яковлев В.П. Антимикробные препараты группы фторхинолонов; http://old.consilium-medicum.com/media/consilium/06_01/35.shtml
4. Pestova E, Beyer R, Cianciotto NP et al. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 2000–4.
5. Pestova E, Millichap J, Noskin G, Peterson L. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000; 45: 583–90,
6. Страчунский Л.С., Веселов А.В., Кречиков В.А. Моксифлоксацин: настоящее и будущее ступенчатой терапии. Клинич. микробиология и антимикробная химиотерапия. 2003; 5 (1): 19–31.
7. Яковлев С.В., Мохов О.И. Моксифлоксацин – препарат нового поколения фторхинолонов для лечения инфекций дыхательных путей. Инфекции и антимикробная терапия. 2000; 2: 104–9.
8. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci 1997; 94: 13991–6.
9. Zhao X, Wang J-Y, Xu C et al. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother 1998; 42: 956–8.
10.  Zhao B-Y, Pine R, Domagala J, Drlica K. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999; 43: 661–6.
11. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45 (12): 3544–7.
12. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infection. Antimicrob Agents Chemother 2004; 48 (3): 1012–6.
13. Яковлев С.В., Суворова М.П. Эффективность моксифлоксацина при респираторных и абдоминальных инфекциях; http://www.t-pacient.ru/archive/tp10-09/tp10-09_606.html
14. Синопальников А.И., Зайцев А.А. Современный взгляд на фармакотерапию обострений хронической обструктивной болезни легких. Лечащий врач. 2009; 10: 45–9.
15. Li Xilin Х, Zhao Х, Drlica К. Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin. Antimicrob Agents Chemother 2002; 46 (2); 522–4.
16. Wilson R, Anzueto A, Miravitlles M et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40 (1): 17–27.
17. Wilson R, Anzueto A, Miravitlles M et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis 2011; 6: 373–83.
18. Gotfried MH, Grossman RF. Short-course fluoroquinolones in acute exacerbations of chronic bronchitis. Expert Rev Respir Med 2010; 4 (5): 661–72.
19. Anzueto A, Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med 2010; 104 (10): 1396–403.
20. Miravitlles M, Llor C, Molina J et al. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. Int J Chron Obstruct Pulmon Dis 2010; 18: 11–9.
21. Sethi S, Jones PW, Theron MS et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 28: 11–20.
22. Samra Z, Rosenberg S, Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin J Chemother 2011; 23 (2): 77–9.
23. Елисеева Е.В., Торговицкая И.П., Хамошина М.Б. Эмпирическая антибиотикотерапия острого сальпингоофорита. Владивосток: Дальнаука, 2009.
24. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
25. Fan A, Yue Y, Geng N et al. Aerobic vaginitis and mixed infections: comparison of clinical and laboratory findings. Arch Gynecol Obstet 2012.
26. Kampougeris G, Antoniadou А, Kavouklis Е et al. Penetration of moxifloxacin into the human aqueous humour after oral administration. Br J Ophthalmol 2005; 89 (5): 628–31.
27. Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg 2012; pii: S0886-3350(12)01196-0, doi: 10,1016/ j.jcrs.2012.07.031.
28. Granet D, Lichtenstein SJ, Onofrey B, Katz JA. An assessment of the tolerability of moxifloxacin 0,5% compared to azithromycin 1,0% in Dura Site. Clin Ophthalmol 2007; 1 (4): 519–25.
29. Durrie DS, Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0,5% ophthalmic solution and gatifloxacin 0,3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocul Pharmacol Ther 2005; 21 (3): 236–41.
30. Белобородов В.Б. Применение фторхинолонов: проблемы резистентности. Cons. Med. 2005; 2: 13–7.
31. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 2012; 72 (6): 17–32.
32. Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis 2011; 53 (11): 1074–80,
33. Mu YP, Liu RL, Wang LQ. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. Int J Clin Pract 2012; 66 (2): 210–7.
34. Яковлев В.П., Светухин А.М., Блатун Л.А. и др. Ступенчатое применение моксифлоксацина при лечении больных с инфекциями кожи и мягких тканей. Инфекции и антимикробная терапия. 2007; 1: 11–4.
35. Gyssens IC, Dryden M, Kujath P et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacinmonotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011; 66 (11): 2632–42.
36. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 (Suppl. 3): 35–44.
37. Choi WS, Kim MJ, Park DW et al. Clarithromycin and amikacin vs clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study. Clin Microbiol Infect 2011; 17 (7): 1084–90,
38. Kern WV, Marchetti O, Drigona L et al. Oral moxifloxacin versus ciprofloxacin plus amoxicillin/clavulanic acid for low-risk febrile neutropenia – a prospective, double-blind, randomised, multicentre EORTC-Infectious Diseases Group (IDG) Trial (protocol 46001, IDG trial XV). 18th Eur Congr Clin Microbiol Infect Dis. Barcelona, Spain, 2008 (Abs.); p. 1548.
39. Григорьевская З.В. Сравнительная эффективность моксифлоксацина и ципрофлоксацина при профилактике фебрильной нейтропении у онкогематологических больных. Сибирск. онкологич. журн. 2010; 4 (40): 5–9.
40. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs RD 2012; 12 (2): 71–100.

Е.В.Елисеева, Р.К.Гончарова, Т.Н.Седых, Ю.В.Феоктистова 

Кафедра общей и клинической фармакологии Владивостокского государственного медицинского университета